STRUCTURE THERAPEUTICS INC. - AMERICAN DEPOSITARY

27,50

06-января-25 15:45:00

15 мин. задержка

Акции

-0,26

-0,94%

Сегодняшний диапазон

27,05 - 28,39

ISIN

N/A

Источник

NASDAQ

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

17 дек 2024 15:01:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

15 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

13 ноя 2024 15:05:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

13 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

31 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

17 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Appoints Angus C. Russell to Board of Directors

27 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces Participation in Upcoming Investor Conferences

26 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

08 авг 2024 15:05:01 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares

07 июн 2024 15:05:25 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

05 июн 2024 18:53:55 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

03 июн 2024 15:09:23 Источник Nasdaq GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

03 июн 2024 06:30:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

09 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

08 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

08 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

18 дек 2023 06:30:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

14 ноя 2023 15:10:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces $300 Million Private Placement Equity Financing

29 сен 2023 06:32:00 Источник Nasdaq GlobeNewswire
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

29 сен 2023 06:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.